CF WELL Pharmacology: Microbiology & Antibiotics
|
|
- Sara George
- 5 years ago
- Views:
Transcription
1 CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017
2 Disclosure I have nothing to disclose regarding the content of this presentation
3 Objectives Describe the prevalence of bacteria that grow in the lungs of CF patients Given a CF patient, develop a treatment regimen (interactive) Describe the recommended monitoring for antibiotics used with CF patients
4 Presentation Outline Cystic fibrosis bacteria prevalence Antibiotics commonly used to treat cystic fibrosis exacerbations Dosing recommendations Monitoring recommendations
5 CYSTIC FIBROSIS BACTERIA PREVALENCE
6 Bacteria Prevalence Cystic Fibrosis Foundation Patient Registry Data: 2014 Annual Patient Report
7 Bacteria Prevalence Cystic Fibrosis Foundation Patient Registry Data: 2014 Annual Patient Report
8 Bacteria Prevalence Top 3 bacteria encountered in cystic fibrosis patients Staphylococcus aureus Methicillin-susceptible Methicillin-resistant Thymidine-dependent Haemophilus influenzae Non-typeable Pseudomonas aeruginosa Non-mucoid Mucoid
9 Staphylococcus aureus Gram positive cocci Most common organism found in respiratory tract of young children with CF Transmission is from person-to-person Members of the same household likely have the same strain Wong et al. Pediatr Pulmonol 2013;48:1151-9
10 Staphylococcus aureus Upper airway colonization believed to precede lower airway infection Once reaches lower airway, infection often persists Children culture positive for S. aureus in first 2 years of life have shown lower FEV 1 and FVC by age 5 Compared to uninfected, matched CF patients Wong et al. Pediatr Pulmonol 2013;48:1151-9
11 Staphylococcus aureus Prophylaxis: Not routinely recommended in the US Studies have linked prophylaxis to increase prevalence of P. aeruginosa infections Studies show no difference in outcomes Weight, radiographic findings, lung function Eradication: Not routinely recommended in the US Eradication is difficult, various rates of efficacy Wong et al. Pediatr Pulmonol 2013;48:1151-9
12 Pseudomonas aeruginosa Gram negative rod Most common organism found in respiratory tract of older CF patients Transmission can be either environmental or person-to-person Usually begins with intermittent isolation from the airways Bendiak G, et al. Semin Respir Crit Care Med 2009;30:587-95
13 Pseudomonas aeruginosa Risk factors for Pseudomonas infection Female gender Homozygous for Phe508-del mutation Decreased lung function Lack of Staphylococcus aureus on recent sputum cultures Little effect on lung function with acquisition of non-mucoid Pseudomonas Significant decline in lung function with development of mucoid Pseudomonas Bendiak G, et al. Semin Respir Crit Care Med 2009;30: Li, et al. JAMA 2005;293:581-8
14 Pseudomonas aeruginosa Prevention: Not Recommended Vaccine against P. aeruginosa has shown variable results Eradication: Recommended Prevent infection with mucoid Pseudomonas Several treatment regimens studied Inhaled antibiotics alone Inhaled antibiotics with oral antibiotics Bendiak G, et al. Semin Respir Crit Care Med 2009;30:587-95
15 Patient Case 4 year old, newly diagnosed patient with cystic fibrosis will be treated for an exacerbation with intravenous antibiotics at home What organism would you want to make sure is empirically treated in this patient? A. Pseudomonas aeruginosa B. Staphylococcus aureus C. Haemophilus influenzae D. Stenotrophomonas maltophilia
16 CYSTIC FIBROSIS ANTIBIOTICS
17 Concentration Dependent
18 Minimal Concentration Dependent
19 Patterns of Bactericidal Activity Concentration-dependent Aminoglycosides Fluoroquinolones Metronidazole Daptomycin Telithromycin Minimal concentrationdependent Penicillins Cephalosporins Carbapenems Monobactams Clindamycin Vancomycin Azithromycin Clarithromycin Linezolid Doxycycline Tigecycline Beta-lactams
20 Choosing Antibiotics in Cystic Fibrosis Pseudomonas aeruginosa Two antipseudomonal antibiotics combination of an aminoglycoside with an antipseudomonal β-lactam In 2009, CF Foundation concluded there is insufficient evidence to support the use of monotherapy for chronic infections Flume et al. Am J Respir Crit Care Med. 2009; 180:802 8 Gibson et al. Am J Respir Crit Care Med. 2003; 168:918-51
21 Choosing Antibiotics in Cystic Fibrosis Pseudomonas aeruginosa Antibiotic susceptibility testing found to not be clinically relevant No correlation found between tobramycin or ceftazidime susceptibilities and clinical response Routine synergy testing is not recommended even for multi-drug resistant (MDR) bacteria Smith et al. Chest. 2003; 123: Aaron et al. Lancet. 2005; 366: Flume et al. Am J Respir Crit Care Med. 2009; 180:802-8.
22 Dosing in Cystic Fibrosis Patients have increased volume of distribution Patients have increased total body clearance Different dosing not limited to antibiotics Most studied class of medications Zobell, et al. Pediatr Pulmonol 2013;48:525-37
23 Aminoglycosides
24 Aminoglycosides Spectrum of activity Burkholderia cepacia Escherichia coli Klebsiella species Enterobacter species Serratia species Citrobacter species Morganella Morganii Acinetobacter species Providencia species Proteus mirabilis Proteus vulgaris Pseudomonas aeruginosa Staphylococcus aureus Synergy with β-lactams or vancomycin Long, et al. Principles and Practice of Pediatric Infectious Diseases, 3rd ed., Pg.1430
25 Aminoglycosides Tissue penetration (percentage of serum) CNS: 5-10% Lungs (epithelial lining fluid): ~30% of peak serum concentrations Urine: 100% Optimal microbiologic efficacy occurs when peak concentration is 8-10 times the MIC Also exhibit a post-antibiotic effect, where activity against bacteria persists when concentration is below the MIC
26 Aminoglycosides Dosing strategies Conventional: every 8 hours Once Daily Dosing: every 24 hours Utilize higher peak concentrations and postantibiotic effect to overcome higher MICs and reduce toxicities 2009: CF Foundation recommends once daily dosing of aminoglycosides is preferred to 3 times daily dosing Flume et al. Am J Respir Crit Care Med 2009;180:802 8
27 Amikacin Pharmacodynamics and pharmacokinetics similar to gentamicin and tobramycin Higher MICs than gentamicin and tobramycin NOT appropriate for once daily dosing PAE only 1-2 hours Typically reserved for bacteria that are resistant to gentamicin and tobramycin Craig et al. J Antimicrob Chemother 1991: Suppl 27:29-40
28 Aminoglycosides Adverse effects Nephrotoxicity Risk increases with elevated trough concentrations Risk increases with dehydration status Ototoxicity Risk increases with prolonged/repeated exposure Risk increases with elevated peak concentrations Electrolyte wasting Potassium and Magnesium
29 Fluoroquinolones Ciprofloxacin Levofloxacin
30 Fluoroquinolones Systemic fluoroquinolones studied in pediatric patients Ciprofloxacin Levofloxacin Ciprofloxacin and levofloxacin have similar spectrums of activities
31 Fluoroquinolones Spectrum of activity Acinetobacter species Escherichia coli Klebsiella pneumoniae Enterobacter species Citrobacter species Proteus species Serratia marcescens Pseudomonas aeruginosa Haemophilus species Moraxella catarrhalis Streptococcus species Enterococcus faecalis Bacillus anthracis Bradley, et al. Principles and Practice of Pediatric Infectious Diseases, 292,
32 Fluoroquinolones Tissue penetration Penetrates most tissues Ciprofloxacin: minimal penetration into CSF For treatment of CF exacerbations, need to get antibiotic into the lungs Epithelial lining fluid concentrations (ELF) Differences exist between ciprofloxacin and levofloxacin
33 Concentration (mg/l) Fluoroquinolones Lung Penetration ELF/Plasma = ELF/Plasma = Ciprofloxacin ELF Plasma Levofloxacin Schuler P, et al. Eur Respir J 1997;10: Drusano GL, et al. Antimicrob Agents Chemother 2002;46:586-9
34 Fluoroquinolones Dosing strategies Ciprofloxacin Oral: 40 mg/kg/day divided Q12H Max dose 1000 mg Q12H IV: 30 mg/kg/day divided Q8 to 12H Max dose 400 mg Q8H Levofloxacin (IV and oral dosing) <10 years: 20 mg/kg/day divided Q12H 10 years: 10 mg/kg/day Q24H Max dose 750 mg Q24H Taketomo et al. Pediatric and Neonatal Dosing Handbook, 22nd ed. Lexi-comp 2015 Courter et al. J Pediatric Infect Dis Soc Feb DOI: /jpids/piw006
35 Fluoroquinolones Adverse effects Bone and joint disorders Use with caution in patients who are: <18 years of age or >60 years of age, requiring concomitant corticosteroids, strenuous physical activity, and renal impairment QTc prolongation Baseline EKG, especially with concomitant medications that prolong the QTc interval
36 Beta Lactams Penicillins Cephalosporins Carbapenems Monobactams
37 Beta Lactams Activity Penicillins Gram positive activity Beta-lactamase inhibitor combos Adds Gram negative activity Extended spectrum PCNs Ex: Piperacillin Adds Pseudomonas activity Cephalosporins Generations 1 3 Gram positive progressing to mostly Gram negative activity Ceftazidime: Pseudomonas coverage Fourth Generation Gram positive and negative activity with Pseudomonas coverage Fifth Generation Gram positive and negative activity with MRSA coverage Carbapenems Gram positive and negative activity with Pseudomonas coverage Monobactams Gram negative activity only including Pseudomonas Bradley, et al. Principles and Practice of Pediatric Infectious Diseases, 292,
38 Beta Lactams Tissue penetration Penetrates most tissues, with most reaching the CSF Dosing CF patients mostly require maximal dosing listed in dosing references Watch for different dosing when need to cover for Pseudomonas Meropenem 40 mg/kg/dose Q8H (max 2000 mg Q8H) vs 20 mg/kg/dose Q8H (max 1000 mg Q8H)
39 Beta Lactams Dosing strategies Intermittent infusion (conventional infusions) Extended infusion Prolonged infusion of antibiotic Typical duration is ½ of the dosing interval Goal is to keep serum concentrations high Continuous infusion Usually given via CADD pumps, or other device Goal is to keep serum concentrations high Can adjust doses based on serum concentrations and MIC of bacteria treating Need to interrupt infusions when aminoglycosides are needed Zobell, et al. Pediatr Pulmonol 2013;48:525-37
40 Beta Lactams Adverse effects Seizures Mostly in renal failure Drug fevers Usually with prolonged therapy Increased AST and ALT Interstitial nephritis
41
42 Vancomycin Spectrum of activity Streptococcus species Enterococcus species Staphylococcus species Actinomyces species Bradley, et al. Principles and Practice of Pediatric Infectious Diseases, 292,
43 Vancomycin Tissue penetration (percentage of serum) CNS: <10% Sternal Bone: 57% Heart Valve: 12% ELF: 18% Lung tissue: 17-24% Bone: 7-13% Fat:14% Muscle: 9% Massias et al. Antimicrob Agents Chemother 1992;36: ; Cruciani et al. J Antimicrob Chemother 1996;38:865-9; Lamer et al Antimicrob Agents Chemother 1993;37:281-6; Daschner et al J Antimicrob Chemother 1987;19:359-62; Graziani et al. Antimicrob Agents Chemother 1988;32:1320-2
44 Vancomycin Dosing mg/kg/dose Q6-8H Dose adjusted based on serum concentrations Dose may start higher if historical dosing information shows the patient requires higher dosing
45 Vancomycin Adverse effects Ototoxicity Associated with serum concentrations >40 mg/l Not seen much any more since compound purified Nephrotoxicity Associated with trough concentrations >10 mg/l No longer considered nephrotoxic since compound purified Increased risk for nephrotoxicity when used in combination with other nephrotoxic medications E.g. aminoglycosides, loop diuretics, etc. Red man syndrome Infusion related reaction
46 Vancomycin Red man syndrome Skin reaction associated with infusion of vancomycin Faster rates of infusion associated with Histamine release Treat initial reaction with diphenhydramine Q6H until symptoms resolved prophylaxis is to slow down rate of infusion Extending infusion duration to 2 hours If still with significant reaction during infusion Give diphenhydramine premedication prior to vancomycin doses
47 Patient Case 10 year old CF patient with history of Pseudomonas aeruginosa, susceptible to tobramycin in cultures. The patient will be started on ceftazidime and another antibiotic to treat the exacerbation. Which of the following is the best choice for this patient? A. Amikacin Q24H B. Tobramycin Q24H C. Tobramycin Q8H D. Piperacillin/Tazobactam Q6H
48 CF ANTIBIOTIC MONITORING
49 Pharmacokinetics Aminoglycosides Peak Goal 8-10 x MIC Trough Low enough to prevent toxicities Typically administered over 30 minutes Monitor serum concentrations regularly
50 Pharmacokinetics Aminoglycosides Conventional dosing Reach steady state concentrations with 3rd dose Peaks and troughs Peak 30 minutes after dose is infused Trough prior to dose Repeat trough concentrations every 5-7 days High Dose Once Daily dosing Never reach steady state concentrations Obtain 2 post-dose serum concentrations, after 1 st or 2 nd dose Repeat serum concentrations every 5-7 days
51 Pharmacokinetics Vancomycin Goal trough is 4-5 x MIC Typically given over 1 hour If dose gets to be >1000 mg/dose (or greater than 25 mg/kg/dose) extend infusion time Monitor serum concentrations regularly Goal trough concentration mcg/ml Goal AUC:MIC of >400
52 Pharmacokinetics Vancomycin Neonates, Infants, Children, Adolescents and Adults Trough levels only Checked around the 3 rd or 4 th dose of the regimen Different if monitoring AUC
53 Antibiotic Monitoring Serum creatinine Ex: Aminoglycosides, vancomycin, piperacillin/tazobactam, ceftazidime, colistimethate Complete blood counts (CBC) Ex: Linezolid, sulfamethoxazole/trimethoprim, meropenem, ceftazidime Liver function tests (LFT) Ex: Piperacillin/tazobactam, rifampin, sulfamethoxazole/trimethoprim, ceftazidime
54 Patient Case 9 year old with cystic fibrosis, admitted for a pulmonary exacerbation. Will be treated with intravenous tobramycin and ceftazidime. Which of the following are the best options for monitoring this patient? A. Serum creatinine only B. Serum creatinine and CBC C. Serum creatinine, CBC, and LFT D. No monitoring required
55 PUTTING IT ALL TOGETHER
56 Patient Case 18 year old with cystic fibrosis, to be treated with antibiotics for pulmonary exacerbation. History of growing Staphylococcus aureus and Pseudomonas aeruginosa. Based on prior admissions, the patient has responded well to intravenous tobramycin, ceftazidime, and sulfamethoxazole/trimethoprim therapy. The following are the most recent culture with susceptibilities:
57 Patient Case Sputum Staphylococcus aureus Antibiotic MIC (mcg/ml) Susceptibility Clindamycin 1 R Erythromycin 8 R Nafcillin 4 R Doxycycline 0.25 S Sulfamethoxazole/trimethoprim 0.25 S Rifampin 0.06 S Vancomycin 1 S
58 Patient Case Sputum Pseudomonas aeruginosa Antibiotic MIC (mcg/ml) Susceptibility Amikacin 2 S Aztreonam 256 R Ceftazidime 256 R Cefepime 256 R Piperacillin/Tazobactam 256 R Ticarcillin/Clavulanate 256 R Meropenem 256 R Colistin 0.5 S Levofloxacin 256 R Tobramycin 1.5 S
59 Patient Case Which of the following is the best option for treatment of this patient s pulmonary exacerbation? A. Intravenous tobramycin, ceftazidime, and sulfamethoxazole/trimethoprim B. Intravenous tobramycin, intravenous colistimethate, and clindamycin C. Intravenous amikacin, ceftazidime, and sulfamethoxazole/trimethoprim D. Intravenous tobramycin, intravenous colistimethate, and intravenous vancomycin
60 Patient Case Based on the treatment regimen of intravenous tobramycin, ceftazidime, and sulfamethoxazole/trimethoprim, which of the following is the best option for monitoring this patient while on these antibiotics? A. Serum creatinine B. CBC C. LFT D. All of the above
61 CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017
Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More informationIntravenous Antibiotic Therapy Information Leaflet
Scottish Adult Cystic Fibrosis Service Ninewells Hospital Dundee Intravenous Antibiotic Therapy Information Leaflet February 2008 Intravenous antibiotic therapy in cystic fibrosis Patients with cystic
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationCefazolin vs. Antistaphyloccal Penicillins: The Great Debate
Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationGeneral Infectious Disease Concepts/Resources
General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal
More informationEradiaction of Resistant Organisms:
Eradiaction of Resistant Organisms: Can we do it and does it help? Noah Lechtzin, MD; MHS Director, Adult CF Program Outline Evidence resistant organisms are bad MRSA, B cepacia, Pseudomonas, Fungal infections
More information* gender factor (male=1, female=0.85)
Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12
More informationAppropriate Antimicrobial Therapy for Treatment of
Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationAntimicrobial Chemotherapy
2016 edition by Claudine El-Beyrouty, PharmD, BCPS Department of Pharmacy Thomas Jefferson University Hospital Brian Roslund, PharmD, BCPS, AQ-ID Department of Pharmacy Thomas Jefferson University Hospital
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationWhat s next in the antibiotic pipeline?
What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics
More informationQUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)
Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationCystic Fibrosis- management of Burkholderia. cepacia complex infections
Guideline Cystic Fibrosis- management of Burkholderia cepacia complex infections Key messages Burkholderia cepacia infections are associated with significant adverse outcomes in Cystic Fibrosis patients
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More informationCUMULATIVE ANTIBIOGRAM
BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA
More informationJerome J Schentag, Pharm D
Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationPharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient
Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationDiagnosis: Presenting signs and Symptoms include:
PERITONITIS TREATMENT PROTOCOL CARI - Caring for Australasians with Renal Impairment - CARI Guidelines complete list ISPD Guidelines: http://www.ispd.org/lang-en/treatmentguidelines/guidelines Objective
More informationEffective 9/25/2018. Contact for previous versions.
Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationRational use of antibiotics
Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationOPAT discharge navigator and laboratory monitoring Select OPAT button for ALL patients that discharge on intravenous antimicrobials
Clinical Monitoring of Outpatient Parenteral Antimicrobial Therapy (OPAT) and Selected Oral Antimicrobial Agents Adult Inpatient/Ambulatory Clinical Practice Guideline Appendix A. Coordinating an OPAT
More informationmicrobiology testing services
microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific
More informationPrinciples of Infectious Disease. Dr. Ezra Levy CSUHS PA Program
Principles of Infectious Disease Dr. Ezra Levy CSUHS PA Program I. Microbiology (1) morphology (e.g., cocci, bacilli) (2) growth characteristics (e.g., aerobic vs anaerobic) (3) other qualities (e.g.,
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationTABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11
Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory
More informationCHSPSC, LLC Antimicrobial Stewardship Education Series
CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationBreaking the Ring. β-lactamases and the Great Arms Race. Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester
Breaking the Ring β-lactamases and the Great Arms Race Bryce M Kayhart, PharmD, BCPS PGY2 Pharmacotherapy Resident Mayo Clinic - Rochester 2015 MFMER slide-1 Disclosures I have no relevant financial relationships
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationAntibiotics 201: Gramnegatives
Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationMICU Antibiotics and Associated Drug Interactions
MICU Antibiotics and Associated Drug Interactions Resistant Bacteria MICU patient are at risk for resistant organisms: Recent hospitalizations From a skilled nursing facility Immunocompromised patients
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More information